Can Botulinum Toxin Have An Effect For Hyperhidrosis?

Start Page: 58

Pertinent Pointers On Ensuring The Correct Dosage

Here is a list of approximate relative potencies of different brands of botulinum toxin A:

1-unit Botox ≈
1-3 units Dysport ≈
50-100 units Myobloc

This is only a rough guide and it probably varies with the use (cosmetic, hyperhidrosis, medical). The median lethal dose (LD-50) estimate in humans is about 3,000 units of Botox. Typical cosmetic use is 30 to 100 Botox units. Typical hyperhidrosis use is 50 to 200 units. Medical uses can be considerably higher.
Aminoglycoside antibiotics may potentiate the effects of botulinum toxin so one should reduce the toxin dose. If using toxin in a patient with neuromuscular disease, reduce the dosage and be very conservative.
Do not use botulinum toxin in women who are pregnant, those who could
be pregnant or lactating women. When one accidentally or intentionally uses botulinum toxin in pregnant women,
complications are rare and may not be related to the BTX-A.29-31 (Intentional use at high doses may be for significant medical problems.)
If a birth defect should occur, even if the relationship between cause and effect is unlikely, process servers might appear at your door.

64
Author(s): 
Suzanne M. Levine, RPT, DPM, and Everett M. Lautin, MD, FACR

1. Strutton DR, Kowalski JW, Glaser DA, Stang PE. US prevalence of hyperhidrosis and impact on individuals with axillary hyperhidrosis: results from a national survey. J Am Acad Dermatol. 2004; 51(2):241-248.
2. Loureiro M de P, de Campos JRM, Kauffman P, Jatene FB, Weigmann S, Fontana A. Endoscopic lumbar sympathectomy for women: effect on compensatory sweat. Clinics (Sao Paulo). 2008; 63(2):189-196.
3. Erbguth FJ. Historical notes on botulism, Clostridium botulinum, botulinum toxin, and the idea of the therapeutic use of the toxin. Mov Disord. 2004; 19(Suppl 8):S2-6.
4. Dhaked RK, Singh MK, Singh P, Gupta P. Botulinum toxin: bioweapon & magic drug. Indian J Med Res. 2010; 132(5):489-503.
5. Sobel J. Botulism. Clin Infect Dis. 2005; 41(8):1167-1173.
6. Smith LA. Botulism and vaccines for its prevention. Vaccine. 2009; 27(Suppl 4):D33-39.
7. Cherington M. Clinical spectrum of botulism. Muscle Nerve. 1998; 21(6):701-710.
8. Hambleton P. Clostridium botulinum toxins: a general review of involvement in disease, structure, mode of action and preparation for clinical use. J Neurol. 1992; 239(1):16-20.
9. Torrens JK. Clostridium botulinum was named because of association with “sausage poisoning.” BMJ. 1998; 316(7125):151-151.
10. Ting PT, Freiman A. The story of Clostridium botulinum: from food poisoning to Botox. Clin Med. 2004; 4(3):258-261.
11. Dolly JO, Aoki KR. The structure and mode of action of different botulinum toxins. Eur J Neurol. 2006; 13(Suppl 4):1-9.
12. O’Flaherty SJ, Janakan V, Morrow AM, Scheinberg AM, Waugh M-CA. Adverse events and health status following botulinum toxin type A injections in children with cerebral palsy. Dev Med Child Neurol. 2011; 53(2):125-130.
13. Medication Guide Botox® Cosmetic(onabotulinum toxin A) for Injection. 2010; Available from: http://www.allergan.com/products/medical_dermatology/botox.htm
14. Li M, Goldberger BA, Hopkins C. Fatal case of BOTOX-related anaphylaxis? J Forensic Sci. 2005; 50(1):169-172.
15. Available at http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2009/ucm175013...
16. Naumann M, Carruthers A, Carruthers J, Aurora SK, Zafonte R, Abu-Shakra S, Boodhoo T, Miller-Messana MA, Demos G, James L, Beddingfield F, VanDenburgh A, Chapman MA, Brin MF. Meta-analysis of neutralizing antibody conversion with onabotulinumtoxinA (BOTOX®) across multiple indications. Mov Disord. 2010; 25(13):2211-2218.
17. Kuehn BM. FDA requires black box warnings on labeling for botulinum toxin products. JAMA. 2009; 301(22):2316.
18. Narayanan UG. Botulinum toxin: does the black box warning justify change in practice? Dev Med Child Neurol. 2011; 53(2):101-102.
19. Botox Product Information: BOTOX® Cosmetic(onabotulinumtoxinA)for injection [Internet]. Available from: http://www.allergan.com/products/prescribing_information.htm
20. Wohlfarth K, Kampe K, Bigalke H. Pharmacokinetic properties of different formulations of botulinum neurotoxin type A. Mov Disord. 2004; 19(Suppl 8):S65-67.
21. Simonetta Moreau M, Cauhepe C, Magues JP, Senard JM. A double-blind, randomized, comparative study of Dysport vs. Botox in primary palmar hyperhidrosis. Br J Dermatol. 2003; 149(5):1041-1045.
22. Güleç A. Dilution of botulinum toxin A in lidocaine vs. in normal saline for the treatment of primary axillary hyperhidrosis: a double-blind, randomized, comparative preliminary study. J Eur Acad Dermatol Venereol. 2011; Epub ahead of print.
23. Shome D, Nair AG, Kapoor R, Jain V. Botulinum toxin A: is it really that fragile a molecule? Dermatol Surg. 2010 ;36(Suppl 4):2106-2110.

image description image description


Post new comment

  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.

More information about formatting options

Image CAPTCHA
Enter the characters shown in the image.